menu
    • menu
    [{"orgOrder":0,"company":"National Institute on Aging","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"AV-1959D","moa":"Amyloid beta protein","graph1":"Neurology","graph2":"Preclinical","graph3":"National Institute on Aging","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"","sponsorNew":"National Institute on Aging \/ National Institute on Aging","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Aging \/ National Institute on Aging"},{"orgOrder":0,"company":"National Institute on Aging","sponsor":"Neuronascent","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"NNI-362","moa":"Allosteric p70S6 kinase","graph1":"Neurology","graph2":"Phase I","graph3":"National Institute on Aging","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"National Institute on Aging \/ National Institute on Aging","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Aging \/ National Institute on Aging"},{"orgOrder":0,"company":"National Institute on Aging","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"DNA-based Vaccine","moa":"Amyloid beta protein","graph1":"Neurology","graph2":"Preclinical","graph3":"National Institute on Aging","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"National Institute on Aging \/ National Institute on Aging","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Aging \/ National Institute on Aging"},{"orgOrder":0,"company":"National Institute on Aging","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Beta-amyloid Vaccine","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"National Institute on Aging","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"","sponsorNew":"National Institute on Aging \/ National Institute on Aging","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Aging \/ National Institute on Aging"},{"orgOrder":0,"company":"National Institute on Aging","sponsor":"Oligomerix","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"OLX-07010","moa":"Tau protein","graph1":"Neurology","graph2":"IND Enabling","graph3":"National Institute on Aging","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institute on Aging \/ National Institute on Aging","highestDevelopmentStatusID":"5","companyTruncated":"National Institute on Aging \/ National Institute on Aging"},{"orgOrder":0,"company":"National Institute on Aging","sponsor":"Cognition Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"CT1812","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"National Institute on Aging","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Institute on Aging \/ National Institute on Aging","highestDevelopmentStatusID":"8","companyTruncated":"National Institute on Aging \/ National Institute on Aging"},{"orgOrder":0,"company":"National Institute on Aging","sponsor":"Neurodon","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"IND Enabling","graph3":"National Institute on Aging","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"National Institute on Aging \/ National Institute on Aging","highestDevelopmentStatusID":"5","companyTruncated":"National Institute on Aging \/ National Institute on Aging"},{"orgOrder":0,"company":"National Institute on Aging","sponsor":"University of California","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"CNDR-51997","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"National Institute on Aging","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"National Institute on Aging \/ National Institute on Aging","highestDevelopmentStatusID":"14","companyTruncated":"National Institute on Aging \/ National Institute on Aging"}]

    Find Clinical Drug Pipeline Developments & Deals by National Institute on Aging

    Menu

    National Institute on Aging

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            National Institute on Aging

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            National Institute on Aging

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CNDR-51997

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : University of California

                            Deal Size : $6.9 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            NIH Awards $6.9 Million to Advance Potential Alzheimer’s Disease Treatment

                            Details : The proceeds will be used to prepare a potential disease-modifying Alzheimer’s treatment, CNDR-51997, which prevented tau from becoming detached from microtubules, for future clinical trials.

                            Brand Name : CNDR-51997

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 21, 2024

                            Lead Product(s) : CNDR-51997

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : University of California

                            Deal Size : $6.9 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            National Institute on Aging

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            National Institute on Aging

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Recipient : Neurodon

                            Deal Size : $3.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Neurodon Awarded Nearly $3 Million from NIH to Advance its Drug for Alzheimer's Disease

                            Details : The funding will be used for continued development and Investigational New Drug (IND)-enabling studies to support clinical translation of the company's small molecule activators of the SERCA enzyme for Alzheimer's disease.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 03, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Recipient : Neurodon

                            Deal Size : $3.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            National Institute on Aging

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            National Institute on Aging

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CT1812

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Recipient : Cognition Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate...

                            Details : CT1812 binds selectively to the sigma-2 receptor complex which is involved in the regulation of key cellular processes, that are damaged by toxic interaction with soluble beta amyloid oligomers and currently in development for mild-to-moderate Alzheimerâ...

                            Brand Name : CT1812

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 28, 2023

                            Lead Product(s) : CT1812

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Recipient : Cognition Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            National Institute on Aging

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            National Institute on Aging

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OLX-07010

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Recipient : Oligomerix

                            Deal Size : $3.4 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Oligomerix Awarded $3.35M from NIH to Support Clinical Development of Tau-Targeting Alzheimer’s Disease Ther...

                            Details : OLX-07010 would potentially fill a significant unmet need with a disease-modifying drug that, if successful, will have a tremendous impact on patient outcomes and reduce the burden on caregivers and society.

                            Brand Name : OLX-07010

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 09, 2022

                            Lead Product(s) : OLX-07010

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Recipient : Oligomerix

                            Deal Size : $3.4 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            National Institute on Aging

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            National Institute on Aging

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DNA-based Vaccine

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : Institute for Molecular Medicine

                            Deal Size : $12.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            PharmaJet Partner, Institute for Molecular Medicine, Launches Clinical Trial for the First in Human Alzheimerâ...

                            Details : The grant supports clinical trials of beta-amyloid vaccines based on DNA and recombinant protein for Alzheimer’s disease. A phase 1 clinical study in the U.S. is expected to begin and the vaccine will be delivered by PharmaJet Tropis® Needle-free Inje...

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            May 24, 2022

                            Lead Product(s) : DNA-based Vaccine

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : Institute for Molecular Medicine

                            Deal Size : $12.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            National Institute on Aging

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            National Institute on Aging

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Beta-amyloid Vaccine

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : Institute for Molecular Medicine

                            Deal Size : $12.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            PharmaJet Partner, Institute for Molecular Medicine, Launches Clinical Trial for the First in Human Alzheimerâ...

                            Details : The grant supports clinical trials of beta-amyloid vaccines based on DNA and recombinant protein for Alzheimer’s disease. A phase 1 clinical study in the U.S. is expected to begin and the vaccine will be delivered by PharmaJet Tropis® Needle-free Inje...

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            May 24, 2022

                            Lead Product(s) : Beta-amyloid Vaccine

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : Institute for Molecular Medicine

                            Deal Size : $12.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            National Institute on Aging

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            National Institute on Aging

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NNI-362

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Recipient : Neuronascent

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Neuronascent Releases Further Positive Results of NNI-362 in A Randomized Phase 1a Trial for Alzheimers Diseas...

                            Details : NNI-362, at the two multi-doses, 120 mg and 240 mg, was shown to significantly reduce p-tau181 levels versus pre-treatment levels in study participants, also showed a significant reduction of an Alzheimer’s disease pathological biomarker.

                            Brand Name : NNI-362

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 30, 2022

                            Lead Product(s) : NNI-362

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Recipient : Neuronascent

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            National Institute on Aging

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            National Institute on Aging

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AV-1959D

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : The Institute for Molecular Medicine

                            Deal Size : $12.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Institute for Molecular Medicine Receives $12 Million NIH Grant to Fund Clinical Trials of AV-1959, First Prev...

                            Details : The funding will support the clinical trials of its beta-amyloid (Aβ) vaccines based on DNA (AV-1959D) and recombinant protein (AV-1959R) for the prevention of Alzheimer's disease (AD).

                            Brand Name : AV-1959D

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 15, 2022

                            Lead Product(s) : AV-1959D

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : The Institute for Molecular Medicine

                            Deal Size : $12.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth